VERAXA starts cell line work for BiTAC T-cell engager
VERAXA Biotech (NASDAQ:VRXA) said it has begun cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) candidate.
VERAXA Biotech (NASDAQ:VRXA) said it has begun cell line development for its lead BiTAC T-cell engager (BiTAC-TCE) candidate.
Alliance Resource Partners (NASDAQ:ARLP) completed its $206.2 million acquisition of oil and gas mineral interests to expand its portfolio.
Arcturus Therapeutics Holdings (NASDAQ:ARCT) announced a strategic collaboration with Thermo Fisher Scientific (NYSE:TMO) to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.
UMH Properties (NYSE:UMH) reported preliminary second-quarter 2026 operating metrics showing total rental and related income increased 10.3% year over year.
Lindsay (NYSE:LNN) reported third-quarter fiscal 2026 revenue of $160.8 million, a 5% decline from $169.5 million in the same period last year.
GFL Environmental (NYSE:GFL) declared a cash dividend of $0.0169 per share for the second quarter of 2026.
United Therapeutics (NASDAQ:UTHR) acquired Thymmune Therapeutics, a preclinical biotechnology company focused on regenerative thymic cell therapies for immune-related diseases.
Ryanair (NASDAQ:RYAAY) reported a 7% increase in June traffic to a new record of 21.2 million guests.
Woodside Energy Group (NYSE:WDS) announced that non-executive director Tony O’Neill will resign from the board effective 1 July 2026.
VEON (NASDAQ:VEON) and Mastercard (NYSE:MA) announced a partnership aimed at expanding access to digital financial services in Ukraine, Kazakhstan, Pakistan, and Uzbekistan.
GARANTA JÁ SEU GRAFA EDGE
Sign up free to unlock this feature
Vamos ativar um teste de 30 dias do Edge como presente de boas-vindas